Malaria Clinical Trial
Official title:
A Trial of Intermittent Preventive Treatment and Home Based Management of Malaria in a Rural Area of The Gambia
Malaria in African countries remains an important cause of mortality and morbidity among young children. The global malaria control strategies include prompt treatment with an effective antimalarial drug, vector control using ITNs or curtains, indoor residual spraying (IRS), and intermittent preventive treatment. However, individually these interventions provide only imperfect protection. Thus, there is a need to investigate whether additional control measures provide added benefit in reducing mortality and morbidity. Therefore, 1312 children under 5 years of age living in villages and hamlets near Farafenni, The Gambia, which form part of the rural Farafenni Demographic Surveillance system (FDSS) in North Bank Region(NBR) were randomly allocated to receive IPTc or placebo from village health workers based in primary health care villages. Treatment with a single dose of sulfadoxine /pyrimethamine plus three doses of amodiaquine or placebo was given to all study subjects at monthly intervals on three occasions during the months of September, October and November. In addition, VHWs were trained to administer treatment with coartem to children if they develop symptoms compatible with malaria during the malaria transmission season. The primary end point was the incidence of clinical attacks of malaria detected during the study.
Goals and Objectives
1. The goal of this project was to determine the degree to which morbidity from malaria
can be prevented in children who receive intermittent preventive treatment(IPTc) with
SP plus amodiaquine and home based management of malaria with Coartem by village health
worker during 2008 malaria transmission season.
2. The objective of the project was to conduct an individually randomized trial of IPTc in
children who receive HMM in North Bank Region an area where malaria transmission is
highly seasonal. This trial will determine whether IPTc adds significant benefit to
HMM.
The study was undertaken in a group of 42 villages and hamlets near Farafenni. The
villages ranged in size from 46 to 1250 inhabitants. The total population of the rural
FDSS catchment area was about 17 000 and that of children under 5 years of age was
about 3000. The area has one general hospital, three health centres and two private
healthcare clinics. There are 18 rural primary health care (PHC) villages in the study
area. PHC villages, each with a population over 400, have mainly been selected plus,
occasionally, others located in relatively isolated areas. In all villages, village
health workers (VHWs) and traditional birth attendants (TBAs) are selected by the
Village Development Committee (VDC) and given 6 to 8 weeks of training with a
standardised curriculum on how to treat common conditions such as uncomplicated
malaria, ARI, diarrhoeal diseases and minor injuries. Thus, VHWs function as primary
health care providers for minor illnesses and injuries for all ages. In addition, the
VHW are expected to work as a community-based health educator. TBAs functioned as birth
attendants, family planning distributors and health educators. Both TBAs and VHWs were
expected to refer serious cases to the local health facility for management. VHWs and
TBAs are supervised by Community Health Nurses who oversee circuits of 4 to 10 PHC
villages. All rural settlements also have a Medical Research Council(MRC) Village
Reporter who carries out sensitization for MRC activities. The bednet coverage in NBR
was estimated to be 50%. However, during the study, details of bed net usage by the
community were assessed.
Recruitment and randomization:
The study was carried in collaboration with the EPI unit of the Department of State for
Health, National Malaria Control Programme and NBR District Health Team. During the
preparatory phase of the study, the design and objectives of the study were discussed
extensively with the NBR District Team and all health care providers working in the
study area. The study team visited all the villages in the study area to explain the
objectives of the trial to village elders, opinion leaders, and heads of women's
groups, village health workers and traditional birth attendants. This was followed by
village meetings, at which the entire community was invited to participate. During
these meetings, agreement to participate in the study was obtained from the villagers.
In addition, parents or guardians of prospective study subjects in the right age group
were visited at home and they were provided with flyers in English and the appropriate
local language (Mandinka, Wollof or Fula). Written informed consent was obtained from
the parent(s) or guardian(s) before a child was enrolled in the study. Enrolled
subjects were provided with a treatment card stamped with a label carrying their name
and study number to facilitate identification at each contact.
Individual randomization was carried out. Study subjects were allocated to receive IPTc
plus HMM or HMM alone.
IPTc and malaria treatment:
Study children received their monthly treatment from a VHW based in a PHC village. The
VWH distributed the trial medication at a central point (usually a health post) during
the first 10 days of the month during September, October and November. Mothers and
carers were asked to bring their children to the central point during the morning when
the VWH was available to distribute the drugs. When a child presented to the central
point for medication, the VHW identified the study subject using the treatment card
held by the mother and matched the information on the treatment card with that on his
register. When he was satisfied that he had correctly identify the study subject, the
correct dosage of the trial medication was given to the study subject. In non-PHC
villages, mothers were asked to bring their children to their nearest PHC village to
receive IPT during the transmission season.
The first dose of treatment was taken under direct supervision of the VHW and the
remaining two doses were given to the mother or guardian of the child with clear
instructions on how to administer the drugs.
At the end of the malaria transmission season, the total number of complete treatment
doses each child in the trial had taken was recorded. Compliance was checked on a
rolling basis throughout the study by assessing the number of correct doses of
medication received.
Malaria treatment and morbidity surveillance during the rainy season Passive
surveillance for malaria was maintained throughout the transmission season. VHW were
instructed to treat febrile illnesses suggestive of malaria with coartem .
Parents/guardians were encouraged to take their child to the VHW at any time the child
became unwell. One field worker was attached to 2-3 village health workers during the
surveillance period. The role of the field worker was to prepare a thick blood film
from children scheduled for treatment by the VHW with coartem for subsequent
confirmation of the diagnosis. VHWs were asked to keep records of children treated for
malaria. In addition, they were asked to refer children who failed to improve on
treatment and those with danger signs to the nearest health centre or AFPRC Hospital
for further evaluation and management.
Any death of a study child was investigated within a month of death using the
post-mortem questionnaire technique.
Cross-sectional survey:
In December, at the end of the malaria transmission season, a cross-sectional survey of
all the children enrolled in the study was undertaken in all the villages. Information
was obtained on demographics, bed net usage, a clinical history was obtained and a
physical examination performed, including abdominal palpation for splenomegaly and
measurement of height, weight and axillary body temperature. A finger-prick blood
sample was obtained from all the children taking part in the cross-sectional survey for
preparation of blood films, a filter paper sample and determination of the haemoglobin
level.
Definitions
The following definitions were used during the course of the study.
Clinical malaria. The primary definition of malaria required:
1. the presence of fever (axillary temperature > 37.5 C) or a history of fever in the
past 24 hours,
2. the absence of any other obvious cause of the fever,
3. the presence of P. falciparum asexual parasitemia above a threshold value of 5,000
parasites per ul (a threshold shown previously to be of value in differentiating
symptomatic malaria from other illnesses associated with co-incidental
parasitemia).
A secondary definition of malaria required only the presence of P. falciparum
parasitemia at any density.
Severe malaria. Severe malaria was defined according to the WHO criteria
Anemia. Anemia was defined as a haemoglobin(Hb) concentration <11 g/dl, moderate anemia
as a Hb concentration < 8 g/dL and severe anemia as an Hb concentration < 5 g/dl.
End-points:
Primary endpoint :
Malaria incidence (the number of study subjects seen at the OPD clinic with clinical
malaria that meet the primary case definitions as indicated above during the
surveillance period).
Secondary endpoints :
1. Malaria incidence (the number of study subjects seen by the VHW with clinical
malaria that meet the secondary case definitions as indicated above during the
surveillance period).
2. the incidence of severe malaria as defined above,
3. the incidence of anaemia among children seen at a hospital or health centre,
4. the prevalence of parasitaemia at the end of malaria transmission season
cross-sectional survey,
5. the prevalence of anaemia at the end of malaria transmission season
cross-sectional survey,
(d) the incidence of all cause hospital admissions,
(e) the incidence of hospital admissions due to malaria,
(f) Coverage with IPTc as measured by the following indicators:
- the proportion of children who received three IPT courses on schedule;
- the proportion of children who received partial or off-schedule IPT courses
- the proportion of children with no IPT.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Completed |
NCT02536222 -
Accelerating the Reduction of Malaria Transmission in Kanel, Ranérou and Linguère Districts
|
Phase 4 |